公开(公告)号：US20150182504A1

公开(公告)日：2015-07-02

申请号：US14592968

申请日：2015-01-09

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： Guohua Pan ,  Jacqueline M. Mason ,  Xin Wei ,  Miklos Feher

IPC: A61K31/416 ,  A61K31/4439 ,  A61K31/5377 ,  A61K31/496

CPC classification number: A61K31/416 ,  A61K31/4439 ,  A61K31/495 ,  A61K31/496 ,  A61K31/497 ,  A61K31/5377

Abstract: Provided herein are methods and compositions for treating a patient with cancer wherein the cancer is characterized by a PTEN gene mutation and/or a PI3K gene mutation. In particular embodiments, the methods comprise administering to the patient a composition comprising a therapeutically effective amount of a PLK4 antagonist.

Abstract translation: 本文提供了用于治疗癌症患者的方法和组合物，其中癌症的特征在于PTEN基因突变和/或PI3K基因突变。 在具体实施方案中，所述方法包括向患者施用包含治疗有效量的PLK4拮抗剂的组合物。

公开(公告)号：US09402828B2

公开(公告)日：2016-08-02

申请号：US14592968

申请日：2015-01-09

Applicant: University Health Network

Inventor： Guohua Pan ,  Jacqueline M. Mason ,  Xin Wei ,  Miklos Feher

IPC: A61K31/553 ,  A61K31/00 ,  A61K31/535 ,  C07D273/00 ,  C07D211/00 ,  A61K31/416 ,  A61K31/4439 ,  A61K31/497 ,  A61K31/495 ,  A61K31/496 ,  A61K31/5377

CPC classification number: A61K31/416 ,  A61K31/4439 ,  A61K31/495 ,  A61K31/496 ,  A61K31/497 ,  A61K31/5377

Abstract: Provided herein are methods and compositions for treating a patient with cancer wherein the cancer is characterized by a PTEN gene mutation and/or a PI3K gene mutation. In particular embodiments, the methods comprise administering to the patient a composition comprising a therapeutically effective amount of a PLK4 antagonist.

Abstract translation: 本文提供了用于治疗癌症患者的方法和组合物，其中癌症的特征在于PTEN基因突变和/或PI3K基因突变。 在具体实施方案中，所述方法包括向患者施用包含治疗有效量的PLK4拮抗剂的组合物。

公开(公告)号：US20250049787A1

公开(公告)日：2025-02-13

申请号：US18723094

申请日：2022-12-21

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： Mark R. Bray ,  Jacqueline M. Mason ,  Xin Wei ,  Gordon Duncan

IPC: A61K31/496 ,  A61K31/635 ,  A61K31/706 ,  A61P35/00 ,  A61P35/02

Abstract: The invention is related to a method of treating a subject with acute myeloid leukemia, acute lymphoblastic leukemia, non-Hodgkin's lymphoma, Burkitt lymphoma, or diffuse large B-cell lymphoma by administration of Compound (I), or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20230144869A1

公开(公告)日：2023-05-11

申请号：US17917995

申请日：2021-04-12

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： Mark R. Bray ,  Jacqueline M. Mason ,  Xin Wei ,  Gordon Duncan

IPC: A61K31/496 ,  A61P37/06

CPC classification number: A61K31/496 ,  A61P37/06

Abstract: Disclosed herein is a method of treating a subject with aberrant cytokine release from a disease or condition or at risk of developing aberrant cytokine release from a disease or condition. The method comprises administering to the subject an effective amount of a compound represented by structural formula (I): (I) or a pharmaceutically acceptable salt thereof. The variables in structural formula (I) are as described herein.